Affinage

SRPK1

SRSF protein kinase 1 · UniProt Q96SB4

Length
655 aa
Mass
74.3 kDa
Annotated
2026-04-28
100 papers in source corpus 44 papers cited in narrative 44 extracted findings

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

SRPK1 is a serine/arginine protein kinase that processively phosphorylates RS domains of SR splicing factors and other RS-containing substrates, thereby governing SR protein nuclear translocation, spliceosome assembly, and alternative splicing decisions across numerous pre-mRNAs. Structural and kinetic studies show that SRPK1 docks the RS domain of its prototypical substrate SRSF1 into an acidic groove distal to the active site, initiating phosphorylation at a defined C-terminal box and sliding the peptide N-terminally in a processive, directional manner with ADP release as the rate-limiting step (PMID:18342604, PMID:21728354, PMID:19477182). Cytoplasmic retention of SRPK1 is maintained by Hsp90/Hsp70 chaperone complexes via cochaperones Hsp40 and Aha1; signal-dependent chaperone dissociation triggers SRPK1 nuclear translocation and consequent changes in SR protein phosphorylation and splice-site selection, controlling outputs including VEGF-A isoform balance, Rac1b inclusion, PD-1 exon skipping, and BRD4 isoform switching (PMID:19240134, PMID:22172722, PMID:24550521, PMID:30568163). Beyond splicing, SRPK1 phosphorylates protamine to drive protamine-to-histone exchange during parental genome reprogramming in fertilized oocytes, phosphorylates the lamin B receptor RS domain, modulates Akt signaling by regulating PHLPP1 recruitment, and is co-opted by viral proteins including HSV-1 ICP27 and HPV E1^E4 to redirect host splicing (PMID:32169215, PMID:24703948, PMID:12660167, PMID:25142587).

Mechanistic history

Synthesis pass · year-by-year structured walk · 21 steps
  1. 1996 High

    Establishing that SRPK1 is a selective serine kinase for SR/RS dipeptide motifs resolved the identity of the kinase responsible for in vivo SR protein phosphorylation at physiologically relevant sites.

    Evidence In vitro kinase assay and tryptic peptide mapping of ASF/SF2

    PMID:8798720

    Open questions at the time
    • Phosphorylation sites on ASF/SF2 not mapped to individual residues
    • In vivo relevance of SRPK1 vs. Clk/Sty not resolved
    • Substrate range beyond ASF/SF2 unknown
  2. 1999 Medium

    Demonstration that SRPK1 phosphorylates lamin B receptor RS repeats extended the substrate repertoire beyond canonical splicing factors to nuclear envelope biology.

    Evidence In vitro kinase assay with synthetic peptides and recombinant LBR

    PMID:10049757

    Open questions at the time
    • Functional consequence of LBR phosphorylation by SRPK1 not demonstrated
    • In vivo relevance not established
    • Only in vitro system used
  3. 2001 Medium

    Genetic complementation of yeast SKY1 deletion by human SRPK1 and antisense knockdown in human cells linked SRPK1 activity to cisplatin sensitivity, revealing a pharmacologically relevant phenotype.

    Evidence Yeast genetic complementation, antisense knockdown in A2780 cells, cisplatin sensitivity assay

    PMID:11585720

    Open questions at the time
    • Mechanistic pathway from SRPK1 activity to cisplatin sensitivity not defined
    • Antisense approach lacks modern genetic rigor
  4. 2003 High

    Discovery that HSV-1 ICP27 physically interacts with SRPK1 and relocalizes it to the nucleus, causing SR protein hypophosphorylation and splicing inhibition, established that viruses hijack SRPK1 to suppress host splicing.

    Evidence Co-immunoprecipitation, in vitro kinase assay, spliceosome assembly assay

    PMID:12660167

    Open questions at the time
    • Structure of ICP27-SRPK1 interface unknown
    • Whether other herpesviruses use the same mechanism not tested
  5. 2005 High

    Mass spectrometric mapping of RS domain phosphorylation by SRPK1 vs. Clk/Sty revealed that SRPK1 selectively targets the N-terminal RS1 segment while Clk/Sty covers additional sites, implying sequential kinase action for full RS domain phosphorylation.

    Evidence Mass spectrometry of RS domain, single-turnover kinetics

    PMID:16223727

    Open questions at the time
    • Sequential action model not validated in vivo
    • Relative timing of SRPK1 and Clk action in cells unknown
  6. 2007 High

    Systematic Arg-to-Lys mutagenesis defined a directional C-to-N 'grab-and-pull' mechanism for SRPK1, resolving how a kinase achieves processive multisite phosphorylation on a linear substrate.

    Evidence Mutagenesis creating protease-sensitive sites to monitor phosphorylation directionality

    PMID:18155240

    Open questions at the time
    • Structural basis of directionality not yet visualized
    • Whether directionality applies to all SR substrates untested
  7. 2008 High

    The crystal structure of SRPK1 bound to ASF/SF2 revealed the acidic docking groove and primed-phosphoserine relay mechanism, providing the first atomic-resolution model for processive directional phosphorylation.

    Evidence X-ray crystallography at 2.9 Å, mutagenesis, in vitro kinase assays

    PMID:18342604

    Open questions at the time
    • Dynamic intermediates during sliding not captured crystallographically
    • Role of RRM2 in allosteric regulation emerging but not fully defined at this stage
  8. 2009 High

    Identification of Hsp40/Aha1 as direct SRPK1-binding cochaperones that anchor it in the cytoplasm via Hsp90/Hsp70, with osmotic stress triggering chaperone release and nuclear translocation, established the signal-dependent localization switch controlling SR protein phosphorylation in vivo.

    Evidence Reciprocal co-immunoprecipitation, subcellular fractionation, osmotic shock, alternative splicing reporter

    PMID:19240134

    Open questions at the time
    • Signals beyond osmotic stress that trigger chaperone release not characterized
    • Post-translational modification driving dissociation unknown at this point
  9. 2009 High

    Biochemical footprinting pinpointed a defined 'initiation box' in the RS1 segment where SRPK1 begins phosphorylation, requiring both the docking groove and the RRM2 domain of SRSF1, refining the processive mechanism to include allosteric substrate-assisted initiation.

    Evidence Engineered footprinting, single-turnover kinetics, deletion and mutagenesis

    PMID:19477182 PMID:19886675

    Open questions at the time
    • Structural visualization of initiation complex lacking
    • Whether initiation box is conserved across all SR substrates unknown
  10. 2011 High

    HDX-MS analysis of the spacer insert domain (SID) and N-terminal extension showed that the SID is intrinsically disordered and serves as a chaperone platform while the N-terminal extension stabilizes the docking groove and accelerates catalytic turnover, defining the regulatory architecture outside the kinase domain.

    Evidence Hydrogen-deuterium exchange mass spectrometry, steady-state kinetics, deletion analysis

    PMID:21600902

    Open questions at the time
    • Atomic-resolution structure of SID in complex with chaperones not solved
    • Contribution of SID to non-SR substrates unknown
  11. 2011 High

    WT1 was shown to directly repress SRPK1 transcription; loss of WT1 elevates SRPK1, hyperphosphorylates SRSF1, and shifts VEGF-A splicing toward pro-angiogenic isoforms, establishing SRPK1 as a transcriptionally regulated nexus between tumor suppressors and angiogenic splicing.

    Evidence ChIP, promoter reporter assay, siRNA knockdown, VEGF splicing RT-PCR, in vivo xenograft

    PMID:22172722

    Open questions at the time
    • Other transcriptional regulators of SRPK1 not yet identified at this time
    • Whether WT1 regulation is tissue-specific not addressed
  12. 2012 High

    Transient-state kinetics revealed that ADP release — not phosphoryl transfer — is rate-limiting during SRPK1's multisite phosphorylation of SRSF1, and that sequences outside the kinase domain (spacer + N-terminal extension) accelerate ADP dissociation, explaining how non-catalytic regions tune processivity.

    Evidence Rapid quench-flow kinetics, viscosometry, deletion analysis, nucleotide exchange assays

    PMID:21728354 PMID:22839969

    Open questions at the time
    • Whether ADP release remains rate-limiting in the cellular context with competing substrates unknown
    • Structural basis of nucleotide release factor function not visualized
  13. 2013 High

    Demonstration that SRPK1 uses a distributive (not processive) mechanism for Tra2β, with the docking groove dispensable, revealed that SRPK1's catalytic strategy is substrate-dependent, not universal.

    Evidence Single-turnover and multiturnover kinetics, docking groove mutants

    PMID:24074032

    Open questions at the time
    • Structural basis for distributive vs. processive substrate discrimination unknown
    • How many SR proteins use each mechanism not surveyed
  14. 2014 High

    Showing that both SRPK1 ablation and overexpression hyperactivate Akt by impairing PHLPP1 phosphatase recruitment established a non-linear, dosage-sensitive signaling role for SRPK1 beyond splicing regulation.

    Evidence MEF transformation assay, genome-wide phosphoproteomics, co-immunoprecipitation, KO cells

    PMID:24703948

    Open questions at the time
    • Direct phosphorylation of PHLPP1 by SRPK1 not shown
    • Whether PHLPP1 regulation is mediated by SRPK1's kinase activity or scaffold function unclear
  15. 2016 High

    Discovery that SRPK1 cooperates symbiotically with CLK1 — binding CLK1's RS-like N-terminus and facilitating release of phosphorylated SR proteins that CLK1 alone cannot release — unified the two-kinase model for efficient spliceosome assembly.

    Evidence Biochemical interaction assays, spliceosome assembly assay, SR protein release assay

    PMID:27397683

    Open questions at the time
    • Structure of SRPK1-CLK1 complex not solved
    • Stoichiometry and regulation of the symbiotic interaction in vivo unknown
  16. 2017 High

    Co-crystal structures of SRPK1 with selective inhibitors revealed a unique binding pocket formed by the helical insert and a hinge backbone flip, providing a structural template for therapeutic SRPK1 inhibitor design.

    Evidence X-ray crystallography of SRPK1–inhibitor complexes, kinase assays, VEGF splicing assay

    PMID:25993998 PMID:28135068

    Open questions at the time
    • In vivo pharmacokinetics and toxicity of these inhibitors not established
    • Selectivity over SRPK2 not fully exploited
  17. 2018 High

    SRPK1 phosphorylates seven of eight sites on HBV core CTD, suppressing nonspecific RNA encapsidation while selective dephosphorylation enables pgRNA packaging, defining SRPK1 as the primary kinase regulating HBV capsid–RNA interactions.

    Evidence Bacterial coexpression, Phos-tag gel, mass spectrometry, mutagenesis, structural analysis

    PMID:30566530

    Open questions at the time
    • Phosphatase(s) mediating selective dephosphorylation not identified
    • Whether SRPK1 phosphorylation of core protein is druggable in infected hepatocytes unknown
  18. 2020 High

    Identification of protamine as an SRPK1 substrate in fertilized oocytes, where phosphorylation disrupts DNA-dependent protamine gel condensates to enable protamine-to-histone exchange, revealed a fundamental non-splicing role for SRPK1 in genome reprogramming.

    Evidence In vitro kinase assay, ATAC-seq, genetic mouse models, phase condensate analysis

    PMID:32169215

    Open questions at the time
    • Upstream signal activating SRPK1 specifically in fertilized oocytes unknown
    • Whether other kinases contribute to protamine dismissal not excluded
  19. 2020 Medium

    Tip60-mediated acetylation was shown to attenuate SRPK1 kinase activity, and LIMK2-mediated phosphorylation was shown to activate it, revealing two opposing post-translational modification pathways controlling SRPK1 output with relevance to cisplatin resistance and metastasis.

    Evidence Western blot for acetylation/phosphorylation, siRNA, drug sensitivity assay (Tip60); SILAC phosphoproteomics, shRNA, mouse metastasis model (LIMK2)

    PMID:32461560 PMID:32859889

    Open questions at the time
    • Specific acetylation and phosphorylation sites on SRPK1 not fully mapped
    • Cross-talk between acetylation and phosphorylation not explored
    • Both findings from single labs
  20. 2020 Medium

    SRPK1 inhibition was shown to switch PD-1 splicing from full-length transmembrane to a soluble exon-3-skipped isoform that prevents T cell suppression, and ibuprofen was found to disassemble a WNK1/GSK3β/SRPK1 complex causing SRPK1 nuclear exclusion and altered Rac1b splicing, expanding the catalog of SRPK1-regulated splicing events to immune checkpoint and cytoskeletal signaling targets.

    Evidence shRNA, SPHINX31 inhibitor, RT-PCR, co-culture T cell assay (PD-1); Co-IP of kinase complex, fractionation, splicing assay (Rac1b/ibuprofen)

    PMID:33315986 PMID:37973660

    Open questions at the time
    • PD-1 isoform regulation not confirmed in primary human T cells
    • WNK1/GSK3β/SRPK1 complex stoichiometry and direct contacts not characterized
    • Both from single labs
  21. 2023 Medium

    A kinase-independent scaffold function was uncovered: the SRPK1 spacer domain binds GSK3β and enhances its autophosphorylation, activating Wnt signaling and promoting EGFR-TKI resistance, demonstrating that SRPK1 can regulate signaling pathways without catalytic activity.

    Evidence Co-immunoprecipitation, kinase-dead mutant studies, promoter binding assay, in vivo gefitinib resistance model

    PMID:36869126

    Open questions at the time
    • Structural basis of spacer–GSK3β interaction unknown
    • Kinase-independent functions in other signaling contexts not explored
    • Single lab finding

Open questions

Synthesis pass · forward-looking unresolved questions
  • Major open questions include the full structural dynamics of the processive sliding intermediate, the identity of all signals and post-translational modifications controlling SRPK1 cytoplasmic-nuclear shuttling, the complete catalog of kinase-dependent vs. kinase-independent functions, and whether therapeutic SRPK1 inhibition can be achieved with acceptable specificity given its dosage-sensitive regulation of both splicing and Akt signaling.
  • No cryo-EM or time-resolved structure of sliding intermediate
  • Systematic identification of all post-translational modifications and their hierarchy missing
  • Kinase-independent scaffold functions incompletely catalogued

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0140096 catalytic activity, acting on a protein 7 GO:0016740 transferase activity 6
Localization
GO:0005634 nucleus 3 GO:0005829 cytosol 2
Pathway
R-HSA-8953854 Metabolism of RNA 7 R-HSA-162582 Signal Transduction 3 R-HSA-74160 Gene expression (Transcription) 3 R-HSA-1266738 Developmental Biology 1
Partners
AHSA1CLK1DNAJC8GSK3BHNRNPA1HSP90AA1PHLPP1SRSF1
Complex memberships
Hsp90/Hsp70/Hsp40/Aha1 chaperone complexWNK1/GSK3β/SRPK1 complex

Evidence

Reading pass · 44 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
1996 SRPK1 phosphorylates SR proteins (including ASF/SF2) specifically at Ser-Arg sites in vitro, with higher specific activity toward ASF/SF2 than Clk/Sty, while Clk/Sty has broader substrate specificity (Ser-Arg, Ser-Lys, Ser-Pro sites). Tryptic peptide mapping confirmed that SRPK1 phosphorylates ASF/SF2 in vitro on sites also phosphorylated in vivo. In vitro kinase assay, tryptic peptide mapping The Journal of biological chemistry High 8798720
2008 Crystal structure (2.9 Å) of SRPK1 in complex with ASF/SF2 reveals that the N-terminal RS domain docks to an acidic groove distal to the active site; phosphorylation of the first serine generates a primed phosphoserine that binds a basic site on the kinase, driving directional (C- to N-terminal) sliding of the RS peptide through the docking groove for processive phosphorylation. X-ray crystallography, in vitro kinase assay, mutagenesis Molecular cell High 18342604
2009 SRPK1 directly binds cochaperones Hsp40/DNAjc8 and Aha1, which mediate dynamic interactions with Hsp70 and Hsp90. Inhibition of Hsp90 ATPase or osmotic shock triggers dissociation of SRPK1 from chaperone complexes, causing translocation from cytoplasm to nucleus, differential SR protein phosphorylation, and altered splice site selection. Co-immunoprecipitation, osmotic shock signaling assay, fractionation, alternative splicing reporter Genes & development High 19240134
2003 HSV-1 protein ICP27 physically interacts with SRPK1, relocalizes it to the nucleus, and alters SRPK1 kinase activity in vitro, resulting in hypophosphorylation of SR proteins and blockade of spliceosome assembly at the pre-spliceosomal complex A stage. Co-immunoprecipitation, in vitro kinase assay, spliceosome assembly assay The EMBO journal High 12660167
2002 SRPK1 and SRPK2 were identified as the major cellular kinases that phosphorylate the arginine-rich C-terminal domain of hepatitis B virus core protein on the same serine residues phosphorylated in vivo; SRPK1 was purified from HuH-7 lysates and identified by mass spectrometry. Affinity purification, mass spectrometry, in vitro kinase assay, immunoblot Journal of virology High 12134018
2011 WT1 binds directly to the SRPK1 promoter and represses SRPK1 transcription. In WT1 mutant cells, elevated SRPK1 hyperphosphorylates SRSF1, shifting VEGF splicing toward pro-angiogenic VEGF165, promoting angiogenesis. Inhibition of SRPK1 reversed splicing and blocked angiogenesis in vitro and in vivo. Chromatin immunoprecipitation, promoter reporter assay, siRNA knockdown, VEGF splicing RT-PCR, in vivo xenograft Cancer cell High 22172722
2014 SRPK1 functions as a tumor suppressor when ablated (induces cell transformation via constitutive Akt activation) and as an oncogene when overexpressed (excess SRPK1 squelches the Akt phosphatase PHLPP1). In both cases, aberrant SRPK1 expression impairs PHLPP1 recruitment to Akt, causing sustained Akt activation. Mouse embryonic fibroblast transformation assay, genome-wide phosphoproteomics, co-immunoprecipitation, KO mouse cells Molecular cell High 24703948
2005 SRPK1 phosphorylates the N-terminal RS1 region of ASF/SF2 efficiently while Clk/Sty phosphorylates all serines throughout the RS domain; both kinases use processive mechanisms but with distinct substrate coverage, suggesting stepwise phosphorylation by sequential kinase action. Mass spectrometry of RS domain, in vitro kinase assay, single-turnover kinetics The Journal of biological chemistry High 16223727
2016 SRPK1 interacts with an RS-like domain in the N-terminus of CLK1 and facilitates release of phosphorylated SR proteins from CLK1, which cannot release them on its own; this symbiotic interaction enables efficient splice-site recognition and spliceosome assembly. Biochemical interaction assays, spliceosome assembly assay, SR protein release assay Molecular cell High 27397683
2020 SRPK1 catalyzes site-specific phosphorylation of protamine in the fertilized oocyte, triggering protamine-to-histone exchange required for parental genome reprogramming. Protamine undergoes DNA-dependent phase transition to gel-like condensates, and SRPK1-mediated phosphorylation opens these structures to enhance protamine dismissal by NPM2 and HIRA-mediated H3.3 deposition. In vitro kinase assay, ATAC-seq, genetic mouse models, phase condensate analysis Cell High 32169215
2007 SRPK1 initiates phosphorylation near the C-terminus of RS1 segment of ASF/SF2 and then moves in an N-terminal direction ('grab-and-pull' mechanism), using region-specific docking at the center of the RS domain with flexible active-site engagement. Arg-to-Lys mutagenesis creating unique protease sites, in vitro kinase assay monitoring phosphorylation progress Journal of molecular biology High 18155240
2009 SRPK1 initiates RS domain phosphorylation at a defined initiation box in the middle of RS1 (at the C-terminal end) and proceeds N-terminally; this initiation requires both the docking groove of SRPK1 and RRM2 of ASF/SF2. Engineered footprinting, single-turnover kinetics, deletion and mutagenesis assays Journal of molecular biology High 19477182
2008 RRM2 of ASF/SF2 allosterically enhances SRPK1 docking and processive phosphorylation: free RRM2 does not bind SRPK1 efficiently unless the docking groove is occupied by the RS domain, and RRM-SRPK1 contact residues control beta-strand folding in RRM2, whose unfolding drives N-terminal serines into the active site. Deletion analysis, single-turnover and multiturnover kinetics, mutagenesis of contact residues Biochemistry High 19886675
1999 SRPK1 phosphorylates the RS-repeat region of lamin B receptor (LBR) with similar kinetics and on the same sites as the dedicated LBR kinase, establishing a new substrate and nuclear envelope-related role for SRPK1. In vitro kinase assay with synthetic peptides and recombinant proteins, site mapping Biochemical and biophysical research communications Medium 10049757
2011 SRPK1 phosphorylation of LBR RS domain is necessary for LBR association with histone H3. Molecular dynamics simulations and GST pull-down assays show that the C-terminal RS region of LBR docks into the acidic groove of SRPK1 similarly to other SR substrates. Molecular dynamics simulation, GST pull-down assay, functional interaction assay Biochimica et biophysica acta Medium 22056509
2011 The large spacer insert domain (SID) of SRPK1 lacks stable hydrogen-bonded structure (intrinsically disordered) and serves as a chaperone interaction platform, while the N-terminal extension adopts stable structure that positively regulates SR protein binding by stabilizing the docking groove. Both regions enhance SR protein turnover by modulating catalytic loop segments. Hydrogen-deuterium exchange mass spectrometry, steady-state kinetics, deletion analysis Journal of molecular biology High 21600902
2012 ADP release (not phosphoryl transfer) is the rate-limiting step during multisite phosphorylation of SRSF1 by SRPK1. Substrate binding affinity, phosphoryl transfer rate, and ADP exchange rate each decline progressively as a function of phosphorylation state in the RS domain. Rapid quench-flow transient-state kinetics, mutagenesis, viscosometric experiments, catalytic trapping Biochemistry High 21728354
2012 Sequences outside the SRPK1 kinase domain — a segment of the spacer insert domain and an N-terminal extension — cooperatively enhance ADP dissociation rate, constituting a nucleotide release factor that accelerates protein substrate phosphorylation. Deletion analysis, nucleotide exchange assays, steady-state kinetics Biochemistry High 22839969
2001 The yeast SRPK1 ortholog SKY1 is required for cisplatin sensitivity; heterologous expression of human SRPK1 in SKY1-deletion yeast restored cisplatin sensitivity. Antisense knockdown of SRPK1 in human A2780 ovarian carcinoma cells conferred ~4-fold cisplatin resistance. Yeast genetic complementation, antisense knockdown, cisplatin sensitivity assay Cancer research Medium 11585720
2014 SRPK1-mediated phosphorylation of SRSF1 controls its nuclear translocation; knockdown of SRPK1 or inhibition of its catalytic activity reduces SRSF1 phosphorylation, prevents nuclear translocation of SRSF1, and decreases inclusion of alternative exon 3b in Rac1 pre-mRNA (Rac1b splicing) in colorectal cells. siRNA knockdown, kinase inhibitor, RT-PCR splicing assay, subcellular fractionation RNA (New York, N.Y.) High 24550521
2007 HPV1 E1^E4 protein is a novel binding partner of SRPK1; E1^E4 binding leads to phosphorylation of E1^E4 polypeptide by SRPK1 in vitro and modulates SRPK1 autophosphorylation. SRPK1 is sequestered into E4 inclusion bodies in terminally differentiated cells within HPV1 warts. Co-immunoprecipitation, in vitro kinase assay, colocalization/immunofluorescence Journal of virology Medium 17360743
2014 HPV1 E1^E4 is a potent inhibitor of SRPK1 kinase activity toward host SR proteins and toward the viral E2 protein in vitro. E1^E4-mediated inhibition of SRPK1 alters E2 nuclear localization in keratinocytes; mutation of E2 SR/RS phosphoacceptor serines or coexpression with SRPK1-inhibitory E1^E4 increases E2 nucleolar accumulation. In vitro kinase assay, mutagenesis of phosphoacceptor sites, immunofluorescence localization Journal of virology High 25142587
2009 Arginine methylation of the ICP27 RGG box regulates ICP27's interaction with SRPK1; hypomethylation (via lysine substitutions or methylation inhibitor) decreased ICP27-SRPK1 interaction as determined by co-immunoprecipitation and colocalization studies. Co-immunoprecipitation, colocalization immunofluorescence, methylation inhibitor treatment Journal of virology Medium 19553338
2005 SRPK1 and SRPK2 overexpression suppresses HBV replication by reducing pgRNA packaging efficiency without affecting core particle formation, and this effect is independent of their kinase activity toward the HBV core protein, as kinase-dead mutants retain the suppressive effect. Overexpression and kinase-dead mutant transfection, HBV replication assay, pgRNA packaging assay Virology Medium 16122776
2018 SRPK1 phosphorylates seven of eight hydroxy amino acids in the HBV core protein CTD; SRPK1-mediated phosphorylation of all seven sites reduces nonspecific RNA encapsidation and alters CTD surface accessibility without major capsid shell structural changes, consistent with a mechanism whereby high phosphorylation suppresses RNA binding while selective dephosphorylation enables pgRNA packaging. Bacterial coexpression system, Phos-tag gel electrophoresis, mass spectrometry, mutagenesis, structural analysis PLoS pathogens High 30566530
2017 SRPK1 inhibitor structures solved by X-ray crystallography reveal that potent inhibitors occupy a binding pocket created by the unique helical insert of SRPK1 and trigger a backbone flip in the hinge region, enabling <10 nM selective inhibition; these compounds inhibit SRSF1 phosphorylation and shift VEGF-A splicing. X-ray crystallography of SRPK1-inhibitor complex, in vitro kinase assay, VEGF splicing assay ACS chemical biology High 28135068
2015 X-ray crystal structure of SRPK1 bound to SRPIN340 solved; a pharmacophore-based screen identified SRPIN803 as a dual SRPK1/CK2 inhibitor that prevents VEGF production more effectively than SRPIN340 alone. X-ray crystallography, pharmacophore docking, in vitro kinase assay, choroidal neovascularization mouse model Molecular pharmacology High 25993998
2018 SRPKIN-1, the first covalent SRPK1/2 inhibitor, forms a covalent bond with a tyrosine phenol group in the ATP-binding pocket of SRPK1; it selectively inhibits SRPK1/2 across the kinome and attenuates SR protein phosphorylation at submicromolar concentrations, converting pro-angiogenic VEGF-A165a to anti-angiogenic VEGF-A165b. Kinome-wide profiling, covalent inhibitor design, in vitro kinase assay, VEGF splicing assay, retinal neovascularization mouse model Cell chemical biology High 29478907
2017 SRPK1 disulfide bonds within the spacer domain and flanking kinase catalytic domains are required for kinase activity and nuclear localization; systematic cysteine mutagenesis showed that Cys356, Cys386, Cys427, Cys455 in the spacer and Cys188 in the first catalytic domain engage in disulfide bridging that positions the two catalytic subunits for activity. Systematic cysteine mutagenesis, in vitro kinase assay, nuclear localization assay, splicing reporter assay PloS one Medium 28166275
2020 SRPK1 phosphorylates SRSF1 and controls PD-1 alternative splicing: SRPK1 knockdown or inhibition with SPHINX31 switches splicing from full-length transmembrane PD-1 (flPD1) to a soluble exon-3-skipped isoform (ΔEx3PD1) that prevents T cell repression by cancer cells. shRNA knockdown, pharmacological inhibition (SPHINX31), RT-PCR splicing assay, co-culture assay, IL-2 ELISA Cancer immunology, immunotherapy : CII Medium 37973660
2020 Tip60-mediated acetylation of SRPK1 reduces its kinase activity; in cisplatin-resistant breast cancer cells, reduced SRPK1 acetylation and increased phosphorylation/kinase activity favor anti-apoptotic splice variants; restoring SRPK1 acetylation re-sensitizes resistant cells to cisplatin. Western blot for acetylation/phosphorylation, siRNA knockdown, drug sensitivity assay, splicing analysis Communications biology Medium 32461560
2013 SRPK1 uses a distributive mechanism for Tra2β (containing short RS repeats of 1-4 dipeptides) where substrate dissociation is rate-limiting, in contrast to the processive mechanism for SRSF1; the conserved docking groove required for SRSF1 phosphorylation is dispensable for Tra2β phosphorylation. Single-turnover and multiturnover kinetics, docking groove mutants, in vitro phosphorylation assay Biochemistry High 24074032
2020 LIMK2 promotes SRPK1 phosphorylation and thereby activates SRPK1 kinase activity in triple-negative breast cancer cells; LIMK2 inhibition reduces SRPK1 phosphorylation and blocks metastatic attributes similarly to direct SRPK1 inhibition. SILAC-based phosphoproteomics, shRNA knockdown, pharmacological inhibition, mouse metastasis model Oncogenesis Medium 32859889
2016 SRPK1 and Akt phosphorylate the RS domain of lamin B receptor (LBR) with distinct specificity: all RS serines are phosphorylated by SRPK1 while Akt selectively targets Ser80 and Ser82, demonstrating that Akt directly phosphorylates an RS domain-containing protein. In vitro kinase assay with synthetic peptides and recombinant mutants, 3D-modeling, molecular dynamics PloS one Medium 27105349
2010 The ratio of SRPK1 to its isoform SRPK1a regulates erythroid differentiation in K562 cells: overexpression of SRPK1a or siRNA-mediated knockdown of SRPK1 both decreased proliferation and induced globin synthesis. Mass spectrometry of SRPK1a-associated proteins identified RNA helicases, hnRNPs, and ribosomal proteins as interactors. Stable overexpression, siRNA knockdown, differentiation assay, mass spectrometry of co-purified proteins Biochimica et biophysica acta Medium 20708644
2021 SRPK1-mediated SRSF1 phosphorylation regulates VEGFR1 pre-mRNA alternative splicing in endothelial cells downstream of FGF-2 signaling, generating soluble VEGFR1 splice variants that contribute to FGF-2-mediated angiogenic functions. FGF-2 activates a SRSF1/SRSF3/SRPK1 axis. siRNA knockdown, 3D collagen sprouting assay, in vivo angiogenesis models, RT-PCR splicing assay BMC biology Medium 34433435
2016 MALAT1 lncRNA physically interacts with both SRPK1 and SRSF1, and promotes SRPK1-catalyzed SRSF1 phosphorylation, thereby increasing AKAP-9 expression; overexpression of SRPK1 after MALAT1 knockdown restored SRSF1 phosphorylation and AKAP-9 levels. Co-immunoprecipitation (MALAT1 with SRPK1 and SRSF1), SRPK1 knockdown/overexpression, western blot for phospho-SRSF1 Oncotarget Medium 26887056
2023 SRPK1 promotes EGFR-TKI (gefitinib) resistance through a kinase-independent mechanism: the SRPK1 spacer domain binds GSK3β and enhances GSK3β autophosphorylation at Ser9, activating Wnt pathway and increasing Bcl-X expression; SRPK1 also facilitates LEF1/β-catenin binding to the EGFR promoter to increase EGFR expression. Co-immunoprecipitation, kinase-dead mutant studies, promoter binding assay, in vitro and in vivo gefitinib resistance assay Oncogene Medium 36869126
2024 METTL3-mediated m6A methylation of SRPK1 mRNA stabilizes it in an IGF2BP2-dependent manner; elevated SRPK1 then interacts with hnRNPA1 (modulator of PKM splicing), upregulating PKM2 and promoting aerobic glycolysis in lung adenocarcinoma. m6A epitranscriptomic microarray, RIP, MeRIP, RNA stability assay, co-immunoprecipitation, metabolic quantification Cellular & molecular biology letters Medium 39095708
2020 Ibuprofen promotes disassembly of a WNK1/GSK3β/SRPK1 protein kinase complex without inhibiting any of these kinases, exposing GSK3β Ser9 to AKT-mediated inhibitory phosphorylation, which results in nuclear exclusion of SRPK1 and SRSF1 hypophosphorylation, preventing RAC1B alternative splicing. Co-immunoprecipitation of kinase complex, subcellular fractionation, phosphorylation western blot, splicing assay Oncotarget Medium 33315986
2018 SRPK1 inhibition in AML leads to a switch from the short to the long BRD4 isoform at mRNA and protein levels, causing BRD4 eviction from leukemogenic loci (BCL2, MYC), cell cycle arrest, and leukemic cell differentiation; this isoform switch mediates at least part of the anti-leukemic effects. RNA-seq isoform analysis, shRNA knockdown, pharmacological inhibition, mouse transplantation model Nature communications Medium 30568163
2019 In tumor endothelium, WT1(-KTS) isoform directly binds and activates the promoters of both Srpk1 and Srsf1; conditional vessel-specific knockout of Wt1 reduced Srpk1 and Srsf1 expression and induced a shift toward antiangiogenic VEGF120 isoform. Promoter binding assay (chromatin/reporter), conditional knockout mouse model, RT-PCR splicing assay Cells Medium 30641926
2020 WT1 activates SRPK1 transcription in cancer cells through a canonical WT1 binding site adjacent to the transcription start site; the transcriptional corepressor BASP1 reverses this activation. Both WT1 and BASP1 co-precipitated with the SRPK1 promoter by ChIP. ChIP, promoter reporter assay, siRNA knockdown, Co-IP Biochimica et biophysica acta. Gene regulatory mechanisms Medium 33017668
2021 USP39 directly binds SRSF1 and SRPK1 via its 101-565 fragment, promotes SRSF1 phosphorylation, and regulates VEGF-A alternative splicing, reducing VEGF-A165b expression; USP39 knockdown restores VEGF-A165b levels in renal cell carcinoma cells. Affinity purification/mass spectrometry, co-immunoprecipitation, western blot for phospho-SRSF1, RT-PCR splicing assay Cancer cell international Medium 34544400

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2011 WT1 mutants reveal SRPK1 to be a downstream angiogenesis target by altering VEGF splicing. Cancer cell 212 22172722
1996 SRPK1 and Clk/Sty protein kinases show distinct substrate specificities for serine/arginine-rich splicing factors. The Journal of biological chemistry 175 8798720
2009 Regulation of SR protein phosphorylation and alternative splicing by modulating kinetic interactions of SRPK1 with molecular chaperones. Genes & development 160 19240134
2017 MicroRNA-1296 inhibits metastasis and epithelial-mesenchymal transition of hepatocellular carcinoma by targeting SRPK1-mediated PI3K/AKT pathway. Molecular cancer 150 28606154
2003 ICP27 interacts with SRPK1 to mediate HSV splicing inhibition by altering SR protein phosphorylation. The EMBO journal 150 12660167
2014 Serine-arginine protein kinase 1 (SRPK1) inhibition as a potential novel targeted therapeutic strategy in prostate cancer. Oncogene 127 25381816
2012 Abnormal expression of the pre-mRNA splicing regulators SRSF1, SRSF2, SRPK1 and SRPK2 in non small cell lung carcinoma. PloS one 127 23071587
2002 Identification of SRPK1 and SRPK2 as the major cellular protein kinases phosphorylating hepatitis B virus core protein. Journal of virology 123 12134018
2014 Both decreased and increased SRPK1 levels promote cancer by interfering with PHLPP-mediated dephosphorylation of Akt. Molecular cell 112 24703948
2015 Tumor cell migration screen identifies SRPK1 as breast cancer metastasis determinant. The Journal of clinical investigation 108 25774502
2018 SRPKIN-1: A Covalent SRPK1/2 Inhibitor that Potently Converts VEGF from Pro-angiogenic to Anti-angiogenic Isoform. Cell chemical biology 104 29478907
2014 Targeting SRPK1 to control VEGF-mediated tumour angiogenesis in metastatic melanoma. British journal of cancer 102 25010863
2008 A sliding docking interaction is essential for sequential and processive phosphorylation of an SR protein by SRPK1. Molecular cell 97 18342604
2021 FGF-2 promotes angiogenesis through a SRSF1/SRSF3/SRPK1-dependent axis that controls VEGFR1 splicing in endothelial cells. BMC biology 95 34433435
2014 Phosphorylation of SRSF1 by SRPK1 regulates alternative splicing of tumor-related Rac1b in colorectal cells. RNA (New York, N.Y.) 92 24550521
2017 Development of Potent, Selective SRPK1 Inhibitors as Potential Topical Therapeutics for Neovascular Eye Disease. ACS chemical biology 86 28135068
2015 Involvement of SRPK1 in cisplatin resistance related to long non-coding RNA UCA1 in human ovarian cancer cells. Neoplasma 84 25967360
2015 Involvement of SRPK1 in cisplatin resistance related to long non-coding RNA UCA1 in human ovarian cancer cells. Neoplasma 83 25866223
2016 Release of SR Proteins from CLK1 by SRPK1: A Symbiotic Kinase System for Phosphorylation Control of Pre-mRNA Splicing. Molecular cell 81 27397683
2005 Mass spectrometric and kinetic analysis of ASF/SF2 phosphorylation by SRPK1 and Clk/Sty. The Journal of biological chemistry 79 16223727
2020 Initiation of Parental Genome Reprogramming in Fertilized Oocyte by Splicing Kinase SRPK1-Catalyzed Protamine Phosphorylation. Cell 78 32169215
2018 SRPK1 maintains acute myeloid leukemia through effects on isoform usage of epigenetic regulators including BRD4. Nature communications 70 30568163
2014 Elevated SRPK1 lessens apoptosis in breast cancer cells through RBM4-regulated splicing events. RNA (New York, N.Y.) 70 25140042
2021 SRPK1/2 and PP1α exert opposite functions by modulating SRSF1-guided MKNK2 alternative splicing in colon adenocarcinoma. Journal of experimental & clinical cancer research : CR 68 33602301
2018 Hepatitis B virus core protein phosphorylation: Identification of the SRPK1 target sites and impact of their occupancy on RNA binding and capsid structure. PLoS pathogens 67 30566530
2013 Topical antiangiogenic SRPK1 inhibitors reduce choroidal neovascularization in rodent models of exudative AMD. Investigative ophthalmology & visual science 61 23887803
2016 Long non-coding RNA MALAT1 increases AKAP-9 expression by promoting SRPK1-catalyzed SRSF1 phosphorylation in colorectal cancer cells. Oncotarget 56 26887056
2001 SKY1 is involved in cisplatin-induced cell kill in Saccharomyces cerevisiae, and inactivation of its human homologue, SRPK1, induces cisplatin resistance in a human ovarian carcinoma cell line. Cancer research 53 11585720
2017 The many faces of SRPK1. The Journal of pathology 47 27859253
2014 Human papillomavirus type 1 E1^E4 protein is a potent inhibitor of the serine-arginine (SR) protein kinase SRPK1 and inhibits phosphorylation of host SR proteins and of the viral transcription and replication regulator E2. Journal of virology 46 25142587
2007 Ordered multi-site phosphorylation of the splicing factor ASF/SF2 by SRPK1. Journal of molecular biology 46 18155240
2018 SRPK1 gene silencing promotes vascular smooth muscle cell proliferation and vascular remodeling via inhibition of the PI3K/Akt signaling pathway in a rat model of intracranial aneurysms. CNS neuroscience & therapeutics 45 30101479
2012 SRPK1 inhibition in vivo: modulation of VEGF splicing and potential treatment for multiple diseases. Biochemical Society transactions 45 22817743
2005 Suppression of hepatitis B virus replication by SRPK1 and SRPK2 via a pathway independent of the phosphorylation of the viral core protein. Virology 45 16122776
2008 Adaptable molecular interactions guide phosphorylation of the SR protein ASF/SF2 by SRPK1. Journal of molecular biology 44 18687337
2004 Resistance to platinum-containing chemotherapy in testicular germ cell tumors is associated with downregulation of the protein kinase SRPK1. Neoplasia (New York, N.Y.) 44 15256051
2020 SRPK1 acetylation modulates alternative splicing to regulate cisplatin resistance in breast cancer cells. Communications biology 42 32461560
2013 SRPK1 contributes to malignancy of hepatocellular carcinoma through a possible mechanism involving PI3K/Akt. Molecular and cellular biochemistry 42 23644876
2013 SRPK1 inhibition modulates VEGF splicing to reduce pathological neovascularization in a rat model of retinopathy of prematurity. Investigative ophthalmology & visual science 41 23761094
2019 Altered VEGF Splicing Isoform Balance in Tumor Endothelium Involves Activation of Splicing Factors Srpk1 and Srsf1 by the Wilms' Tumor Suppressor Wt1. Cells 40 30641926
2015 The influence of SRPK1 on glioma apoptosis, metastasis, and angiogenesis through the PI3K/Akt signaling pathway under normoxia. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 40 25833691
2021 SRPK1/AKT axis promotes oxaliplatin-induced anti-apoptosis via NF-κB activation in colon cancer. Journal of translational medicine 38 34193174
2015 Identification of a Dual Inhibitor of SRPK1 and CK2 That Attenuates Pathological Angiogenesis of Macular Degeneration in Mice. Molecular pharmacology 38 25993998
2015 Serine-arginine protein kinase 1 (SRPK1), a determinant of angiogenesis, is upregulated in prostate cancer and correlates with disease stage and invasion. Journal of clinical pathology 37 26500332
2023 Pathogenic fungi neutralize plant-derived ROS via Srpk1 deacetylation. The EMBO journal 36 36891678
2018 Serine arginine protein kinase 1 (SRPK1): a moonlighting protein with theranostic ability in cancer prevention. Molecular biology reports 35 30535769
1999 SRPK1 and LBR protein kinases show identical substrate specificities. Biochemical and biophysical research communications 35 10049757
2020 LIMK2 promotes the metastatic progression of triple-negative breast cancer by activating SRPK1. Oncogenesis 34 32859889
2008 SRPK1: a cisplatin sensitive protein expressed in retinoblastoma. Pediatric blood & cancer 34 17091485
2013 SRPK1 Dissimilarly Impacts on the Growth, Metastasis, Chemosensitivity and Angiogenesis of Glioma in Normoxic and Hypoxic Conditions. Journal of Cancer 33 24312143
2011 Phosphorylation of the arginine/serine repeats of lamin B receptor by SRPK1-insights from molecular dynamics simulations. Biochimica et biophysica acta 33 22056509
2009 Arginine methylation of the ICP27 RGG box regulates the functional interactions of ICP27 with SRPK1 and Aly/REF during herpes simplex virus 1 infection. Journal of virology 31 19553338
2007 The E1circumflexE4 protein of human papillomavirus interacts with the serine-arginine-specific protein kinase SRPK1. Journal of virology 31 17360743
2020 Human papillomavirus type 16 infection activates the host serine arginine protein kinase 1 (SRPK1) - splicing factor axis. The Journal of general virology 30 32182205
2009 Regiospecific phosphorylation control of the SR protein ASF/SF2 by SRPK1. Journal of molecular biology 29 19477182
2021 USP39 promotes malignant proliferation and angiogenesis of renal cell carcinoma by inhibiting VEGF-A165b alternative splicing via regulating SRSF1 and SRPK1. Cancer cell international 28 34544400
2015 Up-regulation of SRPK1 in non-small cell lung cancer promotes the growth and migration of cancer cells. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 27 26666824
2021 LncRNA Neat1/miR-298-5p/Srpk1 Contributes to Sevoflurane-Induced Neurotoxicity. Neurochemical research 26 34524595
2000 Functional coexpression of serine protein kinase SRPK1 and its substrate ASF/SF2 in Escherichia coli. Nucleic acids research 26 10666475
2022 Serine-Arginine Protein Kinase 1 (SRPK1): a systematic review of its multimodal role in oncogenesis. Molecular and cellular biochemistry 25 35583632
2015 The crucial role of SRPK1 in TGF-β-induced proliferation and apoptosis in the esophageal squamous cell carcinomas. Medical oncology (Northwood, London, England) 24 26099172
2017 SRPK1‑siRNA suppresses K562 cell growth and induces apoptosis via the PARP‑caspase3 pathway. Molecular medicine reports 23 29138847
2014 MiR-9 regulates the post-transcriptional level of VEGF165a by targeting SRPK-1 in ARPE-19 cells. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie 22 25007957
2020 Kinome Profiling of Primary Endometrial Tumors Using Multiplexed Inhibitor Beads and Mass Spectrometry Identifies SRPK1 as Candidate Therapeutic Target. Molecular & cellular proteomics : MCP 21 32994315
2019 SRPK1 facilitates tumor cell growth via modulating the small nucleolar RNA expression in gastric cancer. Journal of cellular physiology 21 30633341
2023 Targeting alternative splicing as a new cancer immunotherapy-phosphorylation of serine arginine-rich splicing factor (SRSF1) by SR protein kinase 1 (SRPK1) regulates alternative splicing of PD1 to generate a soluble antagonistic isoform that prevents T cell exhaustion. Cancer immunology, immunotherapy : CII 20 37973660
2017 The crucial role of SRPK1 in IGF-1-induced EMT of human gastric cancer. Oncotarget 20 29069776
2016 Expression of SRPK1 in gliomas and its role in glioma cell lines viability. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 20 26738865
2011 Regulating SR protein phosphorylation through regions outside the kinase domain of SRPK1. Journal of molecular biology 20 21600902
2023 Serine-arginine protein kinase 1 (SRPK1) promotes EGFR-TKI resistance by enhancing GSK3β Ser9 autophosphorylation independent of its kinase activity in non-small-cell lung cancer. Oncogene 18 36869126
2016 SRPK1 and Akt Protein Kinases Phosphorylate the RS Domain of Lamin B Receptor with Distinct Specificity: A Combined Biochemical and In Silico Approach. PloS one 18 27105349
2002 Bleomycin resistance in mammalian cells expressing a genetic suppressor element derived from the SRPK1 gene. Cancer research 18 12154054
2020 WT1 activates transcription of the splice factor kinase SRPK1 gene in PC3 and K562 cancer cells in the absence of corepressor BASP1. Biochimica et biophysica acta. Gene regulatory mechanisms 17 33017668
2020 Downregulation of long noncoding RNA DLEU1 attenuates hypersensitivity in chronic constriction injury-induced neuropathic pain in rats by targeting miR-133a-3p/SRPK1 axis. Molecular medicine (Cambridge, Mass.) 17 33167866
2018 MiR-216b suppresses colorectal cancer proliferation, migration, and invasion by targeting SRPK1. OncoTargets and therapy 17 29615842
2017 Serine-arginine protein kinase 1 (SRPK1) is elevated in gastric cancer and plays oncogenic functions. Oncotarget 17 28977917
2011 Applying the brakes to multisite SR protein phosphorylation: substrate-induced effects on the splicing kinase SRPK1. Biochemistry 17 21728354
2009 Allosteric interactions direct binding and phosphorylation of ASF/SF2 by SRPK1. Biochemistry 17 19886675
1999 Localization of serine kinases, SRPK1 (SFRSK1) and SRPK2 (SFRSK2), specific for the SR family of splicing factors in mouse and human chromosomes. Genomics 17 10198174
2012 Nucleotide release sequences in the protein kinase SRPK1 accelerate substrate phosphorylation. Biochemistry 16 22839969
2024 N6-methyladenosine-modified SRPK1 promotes aerobic glycolysis of lung adenocarcinoma via PKM splicing. Cellular & molecular biology letters 15 39095708
2022 Icariside Ⅱ Attenuates Palmitic Acid-Induced Endothelial Dysfunction Through SRPK1-Akt-eNOS Signaling Pathway. Frontiers in pharmacology 15 35846993
2020 Identification of a novel and potent small molecule inhibitor of SRPK1: mechanism of dual inhibition of SRPK1 for the inhibition of cancer progression. Aging 15 33291073
2018 miR-126 Functions as a Tumor Suppressor by Targeting SRPK1 in Human Gastric Cancer. Oncology research 15 29510776
2018 SOX2 knockdown inhibits the migration and invasion of basal cell carcinoma cells by targeting the SRPK1-mediated PI3K/AKT signaling pathway. Oncology letters 15 30675221
2017 Evidence for disulfide bonds in SR Protein Kinase 1 (SRPK1) that are required for activity and nuclear localization. PloS one 15 28166275
2017 Chimeric antibody targeting SRPK-1 in the treatment of non-small cell lung cancer by inhibiting growth, migration and invasion. Molecular medicine reports 15 28656224
2013 Splicing kinase SRPK1 conforms to the landscape of its SR protein substrate. Biochemistry 15 24074032
2021 miR-150 and SRPK1 regulate AKT3 expression to participate in LPS-induced inflammatory response. Innate immunity 14 34092081
2014 Akt-ing up on SRPK1: oncogene or tumor suppressor? Molecular cell 14 24813709
2010 The ratio of SRPK1/SRPK1a regulates erythroid differentiation in K562 leukaemic cells. Biochimica et biophysica acta 14 20708644
2005 Synthesis of selective SRPK-1 inhibitors: novel tricyclic quinoxaline derivatives. Bioorganic & medicinal chemistry letters 14 15925511
2022 SRPK1 promotes sepsis-induced acute lung injury via regulating PI3K/AKT/FOXO3 signaling. Immunopharmacology and immunotoxicology 13 36226860
2021 A HIF1A/miR-485-5p/SRPK1 axis modulates the aggressiveness of glioma cells upon hypoxia. Experimental cell research 13 33722639
2021 MiR-155 Inhibits Malignant Biological Behavior of Human Liver Cancer Cells by Regulating SRPK1. Technology in cancer research & treatment 13 33827350
2021 Genetic analysis of sinonasal undifferentiated carcinoma discovers recurrent SWI/SNF alterations and a novel PGAP3-SRPK1 fusion gene. BMC cancer 13 34051734
2011 Distribution of SRPK1 in human brain. Journal of chemical neuroanatomy 12 22019390
2016 Plexin-B1 indirectly affects glioma invasiveness and angiogenesis by regulating the RhoA/αvβ3 signaling pathway and SRPK1. Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine 11 26944058
2020 Ibuprofen disrupts a WNK1/GSK3β/SRPK1 protein complex required for expression of tumor-related splicing variant RAC1B in colorectal cells. Oncotarget 10 33315986
2018 Multi-posttranscriptional regulations lessen the repressive effect of SRPK1 on brown adipogenesis. Biochimica et biophysica acta. Molecular and cell biology of lipids 10 29474929